Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

by | May 6, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: ERW316; Drug: Fulvestrant; Drug: Letrozole

Sponsors: Novartis Pharmaceuticals

Not yet recruiting Conditions: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Drug: ERW316; Drug: Fulvestrant; Drug: Letrozole
Sponsors: Novartis Pharmaceuticals
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *